Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accumulated Expenses (2022 - 2026)

Compass Therapeutics' Accumulated Expenses history spans 5 years, with the latest figure at $1.2 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 20.58% to $1.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.2 million, a 20.58% decrease, with the full-year FY2025 number at $11.4 million, up 307.55% from a year prior.
  • Accumulated Expenses hit $1.2 million in Q1 2026 for Compass Therapeutics, down from $11.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CMPX hit a ceiling of $11.7 million in Q4 2022 and a floor of $526000.0 in Q1 2023.
  • Historically, Accumulated Expenses has averaged $3.9 million across 5 years, with a median of $2.4 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: crashed 83.42% in 2023 and later soared 307.55% in 2025.
  • Tracing CMPX's Accumulated Expenses over 5 years: stood at $11.7 million in 2022, then plummeted by 83.42% to $1.9 million in 2023, then soared by 44.12% to $2.8 million in 2024, then soared by 307.55% to $11.4 million in 2025, then tumbled by 89.59% to $1.2 million in 2026.
  • Business Quant data shows Accumulated Expenses for CMPX at $1.2 million in Q1 2026, $11.4 million in Q4 2025, and $2.5 million in Q3 2025.